Biodexa Pharmaceticals (BDRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has a cash flow conversion efficiency ratio of -0.204x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.33 Million) by net assets ($11.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Biodexa Pharmaceticals to measure how much of total assets are equity-financed.
Biodexa Pharmaceticals - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore BDRX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Biodexa Pharmaceticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodexa Pharmaceticals ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ovoca Gold PLC
IR:OVXA
|
-0.136x |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
Spenda Ltd
AU:SPX
|
-0.443x |
|
DELPHI WORLD MONEY LIMITED
NSE:DELPHIFX
|
0.057x |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
0.220x |
|
Michelmersh Brick Holdings Plc
LSE:MBH
|
0.020x |
|
Magnum Goldcorp Inc
V:MGI
|
0.167x |
|
Hansard Global Plc
LSE:HSD
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual cash flow conversion efficiency of Biodexa Pharmaceticals from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Biodexa Pharmaceticals worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.38 Million | $-5.39 Million | -0.474x | +67.84% |
| 2024-12-31 | $8.32 Million | $-12.26 Million | -1.473x | -0.97% |
| 2023-12-31 | $4.68 Million | $-6.83 Million | -1.459x | +34.54% |
| 2022-12-31 | $3.16 Million | $-7.05 Million | -2.229x | -287.79% |
| 2021-12-31 | $10.45 Million | $-6.01 Million | -0.575x | +58.48% |
| 2020-12-31 | $6.72 Million | $-9.30 Million | -1.384x | -317.29% |
| 2019-12-31 | $19.56 Million | $-6.49 Million | -0.332x | +58.25% |
| 2018-12-31 | $16.92 Million | $-13.45 Million | -0.795x | -112.75% |
| 2017-12-31 | $34.68 Million | $-12.95 Million | -0.374x | -30.52% |
| 2016-12-31 | $45.72 Million | $-13.09 Million | -0.286x | -8.03% |
| 2015-12-31 | $46.89 Million | $-12.42 Million | -0.265x | -103.91% |
| 2014-12-31 | $41.99 Million | $-5.46 Million | -0.130x | +97.77% |
| 2013-12-31 | $760.00K | $-4.44 Million | -5.837x | -1601.94% |
| 2012-12-31 | $-8.28 Million | $-3.22 Million | 0.389x | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more